Stocks · News reference

SL Science Highlights New FDA Drug Master File For GDT Cell-Derived Exosomes

Aug 27, 2026, 12:08 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 27, 2026, 12:19 PMBenzinga Newsdesk
SL Science Highlighted The Filing Of A New Drug Master File With The U.S. FDA Covering Exosomes Derived From Gamma Delta T Cells
SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ:SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of
Read original at benzinga
SLBT
BenzingaAug 11, 2026, 12:02 PMBenzinga Newsdesk
SL Science Announces Publication Of Peer-Reviewed Article In 'Biomedicines' Outlining A Rigorous Development Framework For γδ T Cell Therapy In Glioblastoma
Glioblastoma a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required
Read original at benzinga
SLBT
BenzingaJul 17, 2026, 12:08 PMBenzinga Newsdesk
SL Science Presents Benefits Of Gamma Delta T Cells In Eliminating Glioblastoma In Preclinical Studies At The 2026 World Congress Of Basic And Clinical Pharmacology
SL Science Holding Limited (NASDAQ:SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and
Read original at benzinga
SLBT